No abstract available.
Meningitis*

Emphysematous pyelonephritis is a rare, life-endangering suppurative infection of the renal parenchyma and perirenal tissues. The disease is encountered mainly in the diabetic patient with or without ureteral obstruction and is characterized by the production of intrarenal and occasionally, perirenal gas. We report a case of emphysematous pyelonephritis, treated by left nephrectomy, in 55-year-old diabetic woman.
Female ; Humans ; Middle Aged ; Nephrectomy ; Pyelonephritis* ; Ureteral Obstruction

No abstract available.
Holoprosencephaly*

No abstract available.
Agenesis of Corpus Callosum*

No abstract available.
Lymphadenitis*

No abstract available.
Cardiac Catheterization* ; Cardiac Catheters* ; Child* ; Cineangiography* ; Heart Diseases* ; Heart* ; Humans ; Statistics as Topic*

BACKGROUND: We observed airway remodeling, which is the thickness of the susepithelial layer, in asthmatic patients and inhealthy subjects in order to determine its relationship with severity of disease, such as symptom, bronchial hyperresponsiveness, and degree of acute exacerbation. Moreover, for evaluation of factors contributing to airway remodeling, we analyzed the age, sex, presence of atopy, length of asthmatic history and degree of airway inflammation. METHODS: Thirty-six patients with asthma and ten healthy controls were recruited for the study. The degree of asthma symptom severity was assessed using NIH criteria. Bronchial responsiveness to methacholine was expressed as provocative concentration of methacholine causing a 20% fall in FEV1. The degree of acute exacerbation was assessed by PaCO2 during acute exacerbation. Bronchoscopy, bronchoalveolar lavage(BAL), and bronchial biopsy were performed for all subjects; the total cell counts, differential cell counts and levels of ECP were measured in BAL fluid, and the basement membrane thickness and degree of epithelial shedding were measured in biopsy samples under light microscopy. RESULTS: The mean values of basement membrane thickness were 7.8+/-0.6 micrometer in asthmatics, and 4.1+/-0.5 micrometer in healthy subjects (p<0.05). Basement membrane thickness in patients with severe persistent asthma differed significantly from that of patients with mild intermittent asthma (11.8+/-1.0 micrometer vs 6.5+/-0.7 micrometer p<0.05). A lower level of PC20 for methacholine was observed in asthma with thick basement membrane(> or =7.5 micrometer) compared to those with base- ment membrane less than 7.5micrometer (0.26+/-0.13 mg/ml vs. 0.74+/-0.16 mg/ml, p<0.05). No difference was found between the degree of thickening in patients with different degree of acute exacerbation with age, sex, atopy and lengths of asthmatic history. The degree of thickening was positively correlated to degree of epithelial shedding (r=0.393, p<0.05), but not to the degree of total cell counts, differential cell percentage nor ECP in BAL fluid. CONCLUSION: We confirmed that thickening of the basement membrane is a characteristic finding of asthma. We also demonstrated that it affects symptom severity and bronchial hyperresponsiveness, and is related to degree of epithelial damage rather than duration of asthma history.
Airway Remodeling* ; Asthma* ; Basement Membrane ; Biopsy ; Bronchoscopy ; Cell Count ; Humans ; Inflammation ; Membranes ; Methacholine Chloride ; Microscopy

Mutations of the epidermal growth factor receptor (EGFR) are the strongest predictive factor for response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. EGFR TKIs are approved in Korea as a first-line treatment for lung cancer patients with mutated EGFR. Rapid and accurate EGFR mutation testing is essential for patient selection and establishing targeted therapies with EGFR TKIs. Thus, a standard set of guideline recommendations for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of guideline recommendations for EGFR mutation testing that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.
Humans ; Korea ; Lung ; Lung Neoplasms ; Patient Selection ; Protein-Tyrosine Kinases ; Quinazolines ; Receptor, Epidermal Growth Factor ; Erlotinib Hydrochloride

BACKGROUND AND OBJECTIVES: Estrogen has been reported to inhibit migration and proliferation of vascular smooth muscle cells in vitro and in vivo. Sustained local delivery represents a potential alternative to systemic administrationbecauseitcan achieve higher tissue drug levels at site of balloon injury avoiding systemic side effects. We investigated the effect and mechanism of nanoparticulate sustained-release carrier system using liposome incorporating 17beta-estradiol (E2) on neointimal formation in rat carotid artery balloon injury model. MATERIALS AND METHODS: 17-estradiol benzoate, egg phosphatidylcholine, cholesterol, polyethyleneglycol-phosphatidylethanolamine were mixed to produce E2 -liposome formula where the final concentrations of lipids and E2 were 10 mg/ml and 66 M, respectively. The size of the particle was less than 200 nm. Rat carotid artery balloon injury model was used with Sprague-Dawley rats weighing 350+/-30g. Rats were divided into 3 groups of saline (n=22), liposome (n=46) and E2-liposome (n=46) and received 0.2 ml of each agent at injured site. 1) Rats from all groups were sacrificed at 7 (n=4), 14 (n=6), and 21 (n=12) days after injury, respectively. Morphometric analysis was performed for calculating medial area, neointimal area and I/M (intimal area/medialarea)ratio2)Rats from liposome and E2-liposome group sreceived 100mg/kg of 5-bromo-2'-deoxyuridine (BrdU) at 25, 9 and 1hr before sacrifice at 1 (n=4), 3 (n=4), 7 (n=4), and 14 (n=4) days after injury. BrdU and proliferating cell nuclear antigen (PCNA) stains were performed to elucidate a mechanism of inhibitory effect of E2. RESULTS: 1) There was no increase in the neointimal area in liposome group compared with saline group at 7, 14, and 21 days after injury, respectively. 2) There was 17%, 30%, and 34% reduction of I/M ratio in E2 -liposome group compared with liposome group at 7, 14 and 21 days after injury, respectively. 3) BrdU and PCNA stain revealed that at day 3, labelling index (LI) of media was lower in E2-liposome than in liposome group (p<0.05), and at day 7, LI of neointima was not significantly different between the two groups despite smaller neointimal area in the E2-liposomegroup. CONCLUSION: Nanoparticulateliposomeformula appears to be biocompatible. Local intraluminal infusion of E2 liposome formula after balloon injury of rat carotid artery significantly decreased neointimal formation. The mechanism seems to be the inhibitory effect on the proliferative response of smooth muscle cells in media at an early stage of injury. This formula appears to show potential for clinical applications in the prevention of neointimal formation following balloon angioplsty.
Animals ; Benzoates ; Bromodeoxyuridine ; Carotid Arteries* ; Cholesterol ; Coloring Agents ; Estrogens* ; Hyperplasia* ; Liposomes* ; Muscle, Smooth, Vascular ; Myocytes, Smooth Muscle ; Neointima ; Ovum ; Phosphatidylcholines ; Proliferating Cell Nuclear Antigen ; Rats* ; Rats, Sprague-Dawley

PURPOSE: Heptaplatin (SKI-2053 R) is a new platinum analogue, with a better toxicity profile than cisplatin, and has antitumor activity even in cisplatin resistant cell lines. 5-fluoruracil (5-FU) has shown synergy with platinum compounds. This phase II trial was designed to determine the efficacy and toxicities of heptaplatin/ 5-FU (5-fluorouracil) for treating stomach cancer. MATERIALS AND METHODS: Thirty-two patients with advanced, measurable gastric adenocarcinomas were enrolled in this trial. The treatment consisted of heptaplatin, 400 mg/m2/day (1 hour IV infusion), on day 1 and 5-FU, 800 mg/m2/day (12 hours IV infusion), on days 1 to 5. The cycles were repeated every 3 weeks. RESULTS: Of the 26 evaluable patients, 9 had partial responses and 1a complete response (overall response rate, 38%; 95% confidence interval, 19~57%). The median response duration was 23 weeks (range: 4~60 weeks). The median time to progression was 26 weeks (range: 3~68 weeks). The grades III-IV toxicities were mostly hematological toxicities: leucopenia was observed in 11 patients (35%) and thrombocytopenia 4 (13%). No definite neuropathy was observed. Grade I-II nephropathy was also noted: grade I high BUN/creatinine levels occurred in 5 patients (16%), grade II proteinuria 2 (6%), grade I proteinuria 5 (16%). Neutropenic fever developed in 5 patients (16%) and 1 died of pneumonia in a neutropenic state. CONCLUSION: This study suggests that the regimen of Heptaplatin/5-FU should be effective and have a favorable toxicity profile for the patients suffering with advanced stomach cancer.
Adenocarcinoma ; Cell Line ; Cisplatin ; Drug Therapy ; Fever ; Fluorouracil ; Humans ; Leucovorin* ; Platinum ; Platinum Compounds ; Pneumonia ; Proteinuria ; Stomach Neoplasms* ; Stomach* ; Thrombocytopenia